CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 146 enrolled
Drug / intervention
APOE genotype and Alzheimer's disease risk disclosure +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01434667
NCT01434667N/ACompleted
CompareCT.gov

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

Brigham and Women's Hospital·interventional·Posted Sep 15, 2011·Updated Oct 23, 2018

In Brief

A clinical study evaluating APOE genotype and Alzheimer's disease risk disclosure and Alzheimer's disease risk disclosure for Mild Cognitive Impairment. Completed, enrolled 146 participants across 3 sites.

Detailed Summary

This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment
CountriesUnited States
CollaboratorsNational Human Genome Research Institute (NHGRI), University of Michigan, University of Pennsylvania, Howard University

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 15, 2011
Enrollment StartJan 1, 2010
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 14.8 years ago

Interventions

APOE genotype and Alzheimer's disease risk disclosurebehavioral

Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

Alzheimer's disease risk disclosurebehavioral

Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.